Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Disposal

16th Aug 2006 08:07

BTG PLC16 August 2006 BTG SELLS ONLINE NAVIGATION TRACKING PATENTS London, UK, 16 August 2006: BTG plc (LSE: BGC), the medical innovations company,today announces the sale of its WebNav online navigation tracking patents toTwinTech E.U. II, Limited Liability Company. BTG will receive an immediatepayment of $5 million, as a gross payment before revenue sharing and costs, plusa share of future profits earned by TwinTech E.U. II from commercialisation ofthese patents. BTG launched law suits in 2004 against four parties, including Amazon.com andBarnesandNoble.com, for infringement of a patented technology that enablesefficient tracking of Internet users between websites - a technology used incertain online marketing programmes. All of these cases have been settled. Louise Makin, BTG's Chief Executive Officer, said: "Having settled the existing WebNav litigations, we are pleased to sell thepatents in return for an immediate gain with potential upside from futurelicensing deals. TwinTech E.U. II has the skills and resources to createadditional value from these important patents. "This disposal follows the sale of the Teleshuttle patents to another Delawarecompany earlier this year and underlines the excellent progress we are making inrealising value from our physical sciences assets, allowing us to focus ourresources on our growing life sciences business." Contacts: BTG Financial DynamicsAndy Burrows, Director of Investor Relations Ben Atwell/Anna Keeble+44 (0)20 7575 1741 +44 (0)20 7831 3113Christine Soden, Chief Financial Officer+44 (0)20 7575 1596 About BTG BTG in-licenses, develops and commercialises pharmaceuticals and other medicaltechnologies. With a substantial and growing revenue stream of royalties andmilestone payments from out-licensed products, BTG continues to strengthen itspipeline of preclinical and clinical development programmes. Active in oncology,diseases of ageing, neuroscience, drug repositioning and medical devices, BTGworks from its offices in London, Philadelphia and Osaka with a global partnernetwork of healthcare companies and research organisations. For furtherinformation, visit: www.btgplc.com. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

BTG
FTSE 100 Latest
Value8,596.35
Change99.55